《慢性乙肝防治指南》(2010年版)参考文献

[1] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891.[2] Seeger C, Mason WS. Hepatitis B virus biology[J]. MicrobiolMol Biol Rev,

正文

[1] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891.
[2] Seeger C, Mason WS. Hepatitis B virus biology[J]. Microbiol
Mol Biol Rev, 2000, 64(1):51-68.
[3] Scaglioni PP, Melegari M, Wands JR. Biologic properties
of hepatitis B viral genomes with mutations in the precorepromoter and precore open reading frame[J]. Virology, 1997,
233(2):374-381.
[4] Tran TT, Trinh TN, Abe K. New complex recombinant
genotype of hepatitis B virus identified in Vietnam[J]. J Virol,
2008, 82(11):5657-5663.
[5] Olinger CM, Jutavijittum P, Hubschen JM, et al. Possible newhepatitis B virus genotype, southeast Asia[J]. Emerg Infect Dis,
2008, 14(11):1777-1780.
[6] Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B
is associated with earlier HBeAg seroconversion compared
with hepatitis B virus genotype C[J]. Gastroenterology, 2002,
122(7):1756-1762.
[7] Chu CM, Liaw YF. Genotype C hepatitis B virus infection
is associated with a higher risk of reactivation of hepatitis B
and progression to cirrhosis than genotype B:a longitudinal
study of hepatitis B e antigen-positive patients with normal
aminotransferase levels at baseline[J]. J Hepatol, 2005,
43(3):411-417.
[8] Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype
and DNA level and hepatocellular carcinoma:a prospective
study in men[J]. J Natl Cancer Inst, 2005, 97(4):265-572.
[9] Zhang HW, Yin JH, Li YT, et al. Risk factors for acute
hepatitis B and its progression to chronic hepatitis in Shanghai,
China[J]. Gut, 2008, 57(12):1713-1720.
[10] Hou J, Schilling R, Janssen HL, et al. Genetic characteristics of
hepatitis B virus genotypes as a factor for interferon-induced
HBeAg clearance[J]. J Med Virol, 2007, 79(8):1055-1063.
[11] Jardi R, Rodriguez-Frias F, Schaper M, et al. Analysis
of hepatitis B genotype changes in chronic hepatitis B
infection:influence of antiviral therapy[J]. J Hepatol, 2008,
49(5):695-701.
[12] Liu CJ, Kao JH. Genetic variability of hepatitis B virus and
response to antiviral therapy[J]. Antivir Ther, 2008, 13(5):613-624.
[13] Ganem D, Prince AM. Hepatitis B virus infection--natural
history and clinical consequences[J]. N Engl J Med, 2004,
350(11):1118-1129.
[14] World Health Organization. Hepatitis B([EB/OL])(. Revised
August 2008). [2010-12-9]. http://www.who.int/mediacentre/
factsheets/fs204/en/.
[15] Liang X, Bi S, Yang W, et al. Epidemiological serosurvey
of hepatitis B in China--declining HBV prevalence due to
hepatitis B vaccination[J]. Vaccine, 2009, 27(47):6550-6557.
[16] Liang X, Bi S, Yang W, et al. Evaluation of the impact of
hepatitis B vaccination among children born during 1992-2005
in China[J]. J Infect Dis, 2009, 200(1):39-47.
[17] Lu FM, Zhuang H. Management of hepatitis B in China[J].
Chin Med J (Engl), 2009, 122(1):3-4.
[18] Mast EE, Margolis HS, Fiore AE, et al. A comprehensive
immunization strategy to eliminate transmission of hepatitis
B virus infection in the United States:recommendations of the
Advisory Committee on Immunization Practices (ACIP)
part 1:immunization of infants, children, and adolescents[J].
MMWR Recomm Rep, 2005, 54(RR-16):1-31.
[19] World Health Organization. Hepatitis B[EB/OL]. [2010-
12-9]. http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf.
[20] Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B[J]. Lancet,
2003, 362(9401):2089-2094.
[21] Liaw YF. Natural history of chronic hepatitis B virus infection
and long-term outcome under treatment[J]. Liver Int, 2009,
29(Suppl 1):100-107.
[22] Hui CK, Leung N, Yuen ST, et al. Natural history and disease
progression in Chinese chronic hepatitis B patients in immunetolerant
phase[J]. Hepatology, 2007, 46(2):395-401.
[23] McMahon BJ. The natural history of chronic hepatitis B virus
infection[J]. Hepatology, 2009, 49(5 Suppl):S45-S55.
[24] Liaw YF. Hepatitis flares and hepatitis B e antigen
seroconversion:implication in anti-hepatitis B virus therapy[J].
J Gastroenterol Hepatol, 2003, 18(3):246-252.
[25] Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis
B e antigen to antibody seroconversion in patients with
normal serum aminotransferase levels[J]. Am J Med, 2004,
116(12):829-834.
[26] Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up
of anti-HBe-positive chronic active hepatitis B[J]. Hepatology,
1988, 8(6):1651-1654.
[27] Brunetto MR, Oliveri F, Rocca G, et al. Natural course and
response to interferon of chronic hepatitis B accompanied
by antibody to hepatitis B e antigen[J]. Hepatology, 1989,
10(2):198-202.
[28] Di MV, Lo IO, Camma C, et al. The long-term course of
chronic hepatitis B[J]. Hepatology, 1999, 30(1):257-264.
[29] Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis:natural
history and treatment[J]. Semin Liver Dis, 2006, 26(2):142-152.
[30] Chen YC, Chu CM, Yeh CT, et al. Natural course following the
onset of cirrhosis in patients with chronic hepatitis B:a longterm
follow-up study[J]. Hepatol Int, 2007, 1(1):267-273.
[31] Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after
spontaneous HBeAg seroconversion in patients with chronic
hepatitis B[J]. Hepatology, 2002, 35(6):1522-1527.
[32] Chou YC, Yu MW, Wu CF, et al. Temporal relationship
between hepatitis B virus enhancer II/basal core promoter
sequence variation and risk of hepatocellular carcinoma[J].
Gut, 2008, 57(1):91-97.
[33] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma
across a biological gradient of serum hepatitis B virus DNA
level[J]. JAMA, 2006, 295(1):65-73.
[34] Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and
the risk of hepatocellular carcinoma[J]. N Engl J Med, 2002,
347(3):168-174.
[35] Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk
based on the level of circulating hepatitis B viral load[J].
Gastroenterology, 2006, 130(3):678-686.
[36] Tai DI, Chen CH, Chang TT, et al. Eight-year nationwidesurvival analysis in relatives of patients with hepatocellular
carcinoma:role of viral infection[J]. J Gastroenterol Hepatol,
2002, 17(6):682-689.
[37] 中国疾病预防控制中心.乙型肝炎疫苗儿童计划免疫技术
管理规程(试行)[J].2002.
[38] 夏国良,龚健,王继杰,等.重组乙型肝炎疫苗阻断乙型
肝炎病毒母婴传播方案的保护效果评价[J].中华流行病学
杂志,2003,24(5):362-365.
[39] 邢玉兰,龚晓红,周绍莲,等.阻断围产期母婴传播最佳
免疫方案的研究[J].中华实验和临床病毒学杂志,1990,
4:485-488.
[40] Center for Disease Prevention and Control. Breastfeeding[EB/
OL]. [2010-12-8]. http://www.cdc.gov/breastfeeding/disease/
hepatitis.htm.
[41] World Health Organization. Hepatitis B and breastfeeding[EB/
OL]. [2010-12-8]. http://www.who.int/child_adolescent_
health/documents/ pdfs/hepatitis_b_and_ breastfeeding.pdf.
[42] Zanetti AR, Mariano A, Romano L, et al. Long-term
immunogenicity of hepatitis B vaccination and policy
for booster:an Italian multicentre study[J]. Lancet, 2005,
366(9494):1379-1384.
[43] John TJ, Cooksley G. Hepatitis B vaccine boosters:is there a
clinical need in high endemicity populations[J]. J Gastroenterol
Hepatol, 2005, 20(1):5-10.
[44] U.S. Public Health Service. Updated U.S. Public Health
Service Guidelines for the Management of Occupational
Exposures to HBV, HCV, and HIV and Recommendations for
Postexposure Prophylaxis[J]. MMWR Recomm Rep, 2001,50
(RR-11):1-52.
[45] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒
性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):
324-329.
[46] Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic
monitoring of hepatitis B virus therapy in clinical trials and
practice:recommendations for a standardized approach[J].
Gastroenterology, 2008, 134(2):405-415.
[47] Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan
for the prediction of hepatitis C-related fibrosis:a systematic
review of diagnostic test accuracy[J]. Am J Gastroenterol,
2007, 102(11):2589-2600.
[48] Scot t DR, Levy MT. Live r t r ans i ent e l a s togr aphy
(Fibroscan):a place in the management algorithms of
chronic viral hepatitis[J]. Antivir Ther, 2010, 15(1):1-11.
[49] Lok AS, McMahon BJ. Chronic hepatitis B:update 2009[J].
Hepatology, 2009, 50:661-662.
[50] Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg
positive chronic hepatitis reduces progression to cirrhosis and
hepatocellular carcinoma[J]. J Hepatol, 2007, 46(1):45-52.
[51] Manesis EK, Hadziyannis SJ. Interferon alpha treatment andretreatment of hepatitis B e antigen-negative chronic hepatitis
B[J]. Gastroenterology, 2001, 121(1):101-109.
[52] Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a,
lamivudine, and the combination for HBeAg-positive chronic
hepatitis B[J]. N Engl J Med, 2005, 352(26):2682-2695.
[53] Piratvisuth T, Lau G, Chao YC, et al. Sustained response to
peginterferon alfa-2a (40 kD) with or without lamivudine
in Asian patients with HBeAg-positive and HBeAg-negative
chronic hepatitis B[J]. Hepatol Int, 2008, 2(1):102-110.
[54] Chan HL, Leung NW, Hui AY, et al. A randomized, controlled
trial of combination therapy for chronic hepatitis B:comparing
pegylated interferon-alpha2b and lamivudine with lamivudine
alone[J]. Ann Intern Med, 2005, 142(4):240-250.
[55] Flink HJ, van ZM, Hansen BE, et al. Treatment with Peginterferon
alpha-2b for HBeAg-positive chronic hepatitis
B:HBsAg loss is associated with HBV genotype[J]. Am J
Gastroenterol, 2006, 101(2):297-303.
[56] Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg
and HBsAg loss after long-term follow-up of HBeAgpositive
patients treated with peginterferon alpha-2b[J].
Gastroenterology, 2008, 135(2):459-567.
[57] Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a
alone, lamivudine alone, and the two in combination in patients
with HBeAg-negative chronic hepatitis B[J]. N Engl J Med,
2004, 351:1206-1217
[58] Marcellin P, Bonino F, Lau GK, et al. Sustained response of
hepatitis B e antigen-negative patients 3 years after treatment
with peginterferon alpha-2a[J]. Gastroenterology, 2009,
136(7):2169-2179.
[59] Lok AS, McMahon BJ. Chronic hepatitis B[J]. Hepatology,
2007, 45(2):507-539.
[60] Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm
for the management of chronic hepatitis B virus infection in
the United States:an update[J]. Clin Gastroenterol Hepatol,
2006, 4(8):936-962.
[61] Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis
B virus DNA as outcome predictors during therapy with
peginterferon alfa-2a for HBeAg-positive chronic hepatitis
B[J]. Hepatology, 2008, 47(2):428-434.
[62] Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg
drop:a strong predictor of sustained virological response to
pegylated interferon alfa-2a in HBeAg-negative patients[J].
Hepatology, 2009, 49(4):1151-1157.
[63] Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B
virus surface antigen levels:a guide to sustained response to
peginterferon alfa-2a in HBeAg-negative chronic hepatitis
B[J]. Hepatology, 2009, 49(4):1141-1150.
[64] Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine
treatment in patients with chronic hepatitis B[J]. Gastroenterology,2003, 125(6):1714-1722.
[65] Lai CL, Chien RN, Leung NW, et al. A one-year trial of
lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine
Study Group[J]. N Engl J Med, 1998, 339(2):61-68.
[66] Liaw YF, Leung NW, Chang TT, et al. Effects of extended
lamivudine therapy in Asian patients with chronic hepatitis B.
Asia Hepatitis Lamivudine Study Group[J]. Gastroenterology,
2000, 119(1):172-180.
[67] Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial
treatment for chronic hepatitis B in the United States[J]. N
Engl J Med, 1999, 341(17):1256-1263.
[68] Chien RN, Liaw YF, Atkins M. Pretherapy alanine
transaminase level as a determinant for hepatitis B e antigen
seroconversion during lamivudine therapy in patients with
chronic hepatitis B. Asian Hepatitis Lamivudine Trial
Group[J]. Hepatology, 1999, 30(3):770-774.
[69] Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological
out come dur ing long- t e rm l amivudine the r apy[ J ] .
Gastroenterology, 2003, 124(1):105-117.
[70] Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients
with chronic hepatitis B and advanced liver disease[J]. N Engl
J Med, 2004, 351(15):1521-1531.
[71] Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine
treatment for decompensated cirrhosis resulting from chronic
hepatitis B[J]. Hepatology, 2000, 31(1):207-210.
[72] Perrillo RP, Wright T, Rakela J, et al. A multicenter United
States-Canadian trial to assess lamivudine monotherapy
before and after liver transplantation for chronic hepatitis B[J].
Hepatology, 2001, 33(2):424-432.
[73] Hann HW, Fontana RJ, Wright T, et al. A United States
compassionate use study of lamivudine treatment in
nontransplantation candidates with decompensated hepatitis B
virus-related cirrhosis[J]. Liver Transpl, 2003, 9(1):49-56.
[74] Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of
lamivudine in children with chronic hepatitis B[J]. N Engl J
Med, 2002, 346(22):1706- 1713.
[75] Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et
al. Efficacy of lamivudine in the treatment of children with
chronic hepatitis B[J]. Hepatol Res, 2005, 31(4):217-222.
[76] 姚光弼,崔振宇,姚集鲁,等.国产拉米夫定治疗2200
例慢性乙型肝炎的Ⅳ期临床试验[J].中华肝脏病杂志,
2003,11(2):103-108.
[77] 姚光弼,王宝恩,崔振宇,等.拉米夫定治疗慢性乙型肝炎
三年疗效观察[J].中华内科杂志,2003,42(6):382-387.
[78] 曾民德,茅益民,姚光弼,等.阿德福韦酯治疗HBeAg阳性
的中国慢性乙型病毒性肝炎患者52周的多中心临床研究[J].
中华传染病杂志,2005,23(6):387-394.
[79] Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for
the treatment of hepatitis B e antigen-positive chronic hepatitisB[J]. N Engl J Med, 2003, 348(9):808-816.
[80] Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and
safety of adefovir dipivoxil for the treatment of hepatitis B
e antigen-positive chronic hepatitis B[J]. Hepatology, 2008,
48(3):750-758.
[81] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm
therapy with adefovir dipivoxil for HBeAg-negative
chronic hepatitis B for up to 5 years[J]. Gastroenterology,
2006, 131(6):1743-1751.
[82] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term
therapy with adefovir dipivoxil for HBeAg-negative chronic
hepatitis B[J]. N Engl J Med, 2005, 352(26):2673-2681.
[83] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir
dipivoxil for the treatment of hepatitis B e antigen-negative
chronic hepatitis B[J]. N Engl J Med, 2003, 348(9):800-807.
[84] Lampertico P, Vigano M, Manenti E, et al. Low resistance
to adefovir combined with lamivudine:a 3-year study of 145
lamivudine-resistant hepatitis B patients[J]. Gastroenterology,
2007, 133(5):1445-1451.
[85] Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to
adefovir therapy in lamivudine-resistant HBeAg-negative chronic
hepatitis B[J]. Hepatology, 2007, 45(2):307-313.
[86] Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly
suppresses hepatitis B in HBeAg-negative patients developing
genotypic resistance to lamivudine[J]. Hepatology, 2005,
42(6):1414-1419.
[87] Peters MG, Hann HH, Martin P, et al. Adefovir dipivoxil alone
or in combination with lamivudine in patients with lamivudineresistant
chronic hepatitis B[J]. Gastroenterology, 2004,
126(1):91-101.
[88] Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil
added to ongoing lamivudine in chronic hepatitis B with
YMDD mutant hepatitis B virus[J]. Gastroenterology, 2004,
126(1):81-90.
[89] Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis
of hepatitis B virus recurrence after liver transplantation in
carriers of lamivudine-resistant mutants[J]. Liver Transpl,
2005, 11(5):532-538.
[90] 张雅敏,朱志军,郑虹,等.阿德福韦在预防肝移植后乙
肝复发中的应用[J].中华肝胆外科杂志,2006,12(5):
313-315.
[91] Chang TT, Gish RG, de Man R, et al. A comparison of
entecavir and lamivudine for HBeAg-positive chronic hepatitis
B[J]. N Engl J Med, 2006, 354(10):1001-1010.
[92] Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine
for patients with HBeAg-negative chronic hepatitis B[J]. N
Engl J Med, 2006, 354(10):1011-1020.
[93] Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up
to 96 weeks in patients with HBeAg-positive chronic hepatitisB[J]. Gastroenterology, 2007, 133(5):1437-1444.
[94] Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of
entecavir in nucleoside-naive Japanese patients with chronic
hepatitis B infection[J]. J Hepatol, 2010, 52(6):791-799.
[95] Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for
treatment of lamivudine-refractory, HBeAg-positive chronic
hepatitis B[J]. Gastroenterology, 2006, 130(7):2039-2049.
[96] 姚光弼,计焱焱,任红,等.恩替卡韦治疗拉米夫定失效
慢性乙型肝炎一年的疗效[J].中华传染病杂志,2006,24
(6):385-389.
[97] 姚光弼,朱玫,王宇明,等.恩替卡韦与拉米夫定治疗慢
性乙型肝炎随机、双盲、双模拟对照研究[J].中华内科杂
志,2006,45(11):891-895.
[98] Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial
results:telbivudine Is superior to lamivudine in patients with
chronic hepatitis B[J]. Gastroenterology, 2009, 136(2):486-495.
[99] Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine
in patients with chronic hepatitis B[J]. N Engl J Med, 2007,
357(25):2576-2588.
[100] Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine
in Chinese patients with chronic hepatitis B:Results at 1 year
of a randomized, double-blind trial[J]. Hepatology, 2008,
47(2):447-454.
[101] Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and
early on-treatment response predict the outcomes of 2 years
of telbivudine treatment of chronic hepatitis B[J]. J Hepatol,
2009, 51(1):11-20.
[102] 贾继东,侯金林,尹有宽,等.替比夫定或拉米夫定抗乙
型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志,2007,
15(5):342-345.
[103] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil
fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N
Engl J Med, 2008, 359(23):2442-2455.
[104] Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy
and safety of tenofovir disoproxil fumarate treatment for chronic
hepatitis B[J]. Gastroenterology, 2011, 140(1):132-143.[105] Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA
levels at week 4 of lamivudine treatment predict the 5-year
ideal response[J]. Hepatology, 2007, 46(6):1695-1703.
[106] Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international
workshop:roadmap for management of patients receiving oral
therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol,
2007, 5(8):890-897.
[107] Chan HL, Tang JL, Tam W, et al. The efficacy of thymosin
in the treatment of chronic hepatitis B virus infection:a metaanalysis[
J]. Aliment Pharmacol Ther, 2001, 15(5):1899-1905.
[108] Chien RN, Liaw YF, Chen TC, et al. Efficacy of thymosin
alpha1 in patients with chronic hepatitis B:a randomized,
controlled trial[J]. Hepatology, 1998, 27(5):1383-1387.
[109] Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of
de novo hepatitis B infection in HBsAg-negative patients
undergoing cytotoxic chemotherapy[J]. Gastroenterology,
2006, 131(1):59-68.
[110] 中华医学会感染病学分会肝衰竭与人工肝学组、中华医学会
肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中
华肝脏病杂志,2006,14(9):643-646.
[111] Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis
B-related hepatocellular carcinoma is associated with high
viral load at the time of resection[J]. Am J Gastroenterol, 2008,
103(7):1663-1673.
[112] Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for
patients with HBV-related hepatocellular carcinoma increase
the survival rate through improved liver function[J]. Intern
Med, 2009, 48(1):11-17.
[113] Zhang FK, Liu DG, Jia JD. Antiviral therapy for hepatitis B in
special populations[J]. Antivir Ther, 2010, 15(8):1067-1075.
[114] Sokal EM, Kelly D, Wirth S, et al. The pharmacokinetics and
safety of adefovir dipivoxil in children and adolescents with
chronic hepatitis B virus infection[J]. J Clin Pharmacol, 2008,
48(4):512-517.

医生推荐

 

高速代理IP

多发性骨髓瘤,感染,糖尿病,便秘,感染,抑郁症,贫血,抽搐,脊柱侧弯,性病,。 诊疗文章网 

诊疗文章网 @ 2018